Orchid Pharma Limited has informed the Exchange regarding 'Orchid Pharma Limited has informed the Exchange regarding 'Intimation related to the Scheme of Amalgamation of Dhanuka LaboratoriesLimited ( Amalgamating Company ) with Orchid Pharma Limited ( Company / Amalgamated Company ) and their respective shareholders and creditors( the Scheme ) under Regulation 30 of SEBI (Listing Obligations andDisclosure Requirements) Regulations, 2015, as amended''.
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The National Company Law Tribunal (NCLT), Chennai has pronounced its order on April 29, 2025 (uploaded May 2, 2025) on the proposed amalgamation of Dhanuka Laboratories Limited (unlisted parent company) into Orchid Pharma Limited (listed subsidiary). Under the scheme, Dhanuka Laboratories will merge into Orchid Pharma by absorption, simplifying the group structure. Dhanuka currently holds 69.84% of Orchid Pharma's equity and 14,300 Optionally Convertible Debentures; these will stand cancelled upon implementation. The NCLT has directed meetings of Orchid Pharma's equity shareholders (36,342 shareholders) and unsecured creditors of both companies to be held on June 10, 2025. Meetings of Dhanuka's equity shareholders and secured creditors of both companies have been dispensed with as 100% consent affidavits were submitted. The merger is part of the original 2019 resolution plan under which Dhanuka acquired Orchid Pharma via the IBC process.
For Orchid Pharma's public shareholders, this is a group restructuring where the parent (Dhanuka) merges into the listed subsidiary (Orchid Pharma), cancelling the parent's existing 69.84% stake. This simplifies the corporate structure and may lead to cleaner governance, but existing public shareholders' proportionate ownership in Orchid Pharma continues unchanged.